ReviewCurrent pharmaceutical biotechnology2024
Articulating the Pharmacological and Nanotechnological Aspects of Genistein: Current and Future Prospectives.
Review in Current pharmaceutical biotechnology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Genistein Supplementation Affects Mineral Homeostasis in Rats with Mammary Cancer.Foods (Basel, Switzerland) · 2026Article
- Exploring the anti-inflammatory effects of genistein in an in vitro lipopolysaccharide-induced macrophage model.Scientific reports · 2026Article
- Multidimensional targeting of ischemia-reperfusion injury by genistein: from molecular crosstalk to clinical translation.Frontiers in pharmacology · 2026Review
- Genistein in polycystic ovary syndrome: mechanisms, preclinical evidence, and translational potential.Frontiers in global women's health · 2026Review
- The Supportive Role of Plant-Based Substances in AMD Treatment and Their Potential.International journal of molecular sciences · 2025Review
- Genistein in the Prevention and Treatment of Periodontitis: A Review.Food science & nutrition · 2025Review
- Genistein as a renoprotective agent: mechanistic insights into antioxidant, anti-inflammatory, and fibrosis-regulating pathways.Molecular biology reports · 2025Review
- Recent advancements in genistein nanocarrier systems for effective cancer management.Medical oncology (Northwood, London, England) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Throughout the past several centuries, herbal constituents have been the subject of scientific interest and the latest research into their therapeutic potential is underway. Genistein is a soy-derived isoflavone found in huge amounts in soy, along with the plants of the Fabaceae family. Scientific studies have demonstrated the beneficial effects of genistein on various health conditions. Genistein presents a broad range of pharmacological activities, including anticancer, neuroprotective, cardioprotective, antiulcer, anti-diabetic, wound healing, anti-bacterial, antiviral, skin, and radioprotective effects. However, the hydrophobic nature of genistein results in constrained absorption and restricts its therapeutic potential. In this review, the number of nanocarriers for genistein delivery has been explored, such as polymeric nanoparticles, nanostructured lipid carriers, solid lipid nanoparticles, liposomes, micelles, transferosomes, and nanoemulsions and nanofibers. These nano-formulations of genistein have been utilized as a potential strategy for various disorders, employing a variety of
Indexed as
Identifiers
38902930What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.